| Bioactivity | ISO-1 is a macrophage migration inhibitory factor (MIF) antagonist with an IC50 of 7 μM. | ||||||||||||
| Target | IC50: 7 μM (MIF) | ||||||||||||
| Invitro | ISO-1 (0.1-20 μM; 16 hours) has a slight inhibitory effect on Cox-2 secretion without the addition of recombinant MIF[1]. Western Blot Analysis[1] Cell Line: | ||||||||||||
| In Vivo | ISO-1 (injected intraperitoneally; 3.5-35 mg/kg; twice daily; 2 weeks) improves the survival rate from lethal endotoxemia and shows the anti-inflammatory effect[2].ISO-1 (intraperitoneal injection; 35 mg/kg; twice daily; 3 days) causes a significant reduction in average implant size and decreases Flk1 expression in implants[3]. Animal Model: | ||||||||||||
| Name | ISO-1 | ||||||||||||
| CAS | 478336-92-4 | ||||||||||||
| Formula | C12H13NO4 | ||||||||||||
| Molar Mass | 235.24 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Lubetsky JB, et al. The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents. J Biol Chem. 2002 Jul 12;277(28):24976-82. [2]. Al-Abed Y, et al. ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. J Biol Chem. 2005 Nov 4;280(44):36541-4. [3]. Nothnick WB, et al. Inhibition of macrophage migration inhibitory factor reduces endometriotic implant size in mice with experimentally induced disease. J Endometr. 2011 Sep 30;3(3):135-142. |